GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (OTCPK:OBIMF) » Definitions » Change In Receivables

OBIMF (Ondine Biomedical) Change In Receivables : $-0.10 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Ondine Biomedical Change In Receivables?

Ondine Biomedical's change in receivables for the quarter that ended in Jun. 2024 was $0.07 Mil. It means Ondine Biomedical's Accounts Receivable declined by $0.07 Mil from Dec. 2023 to Jun. 2024 .

Ondine Biomedical's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.11 Mil. It means Ondine Biomedical's Accounts Receivable increased by $0.11 Mil from Dec. 2022 to Dec. 2023 .

Ondine Biomedical's Accounts Receivable for the quarter that ended in Jun. 2024 was $0.17 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ondine Biomedical's Days Sales Outstanding for the six months ended in Jun. 2024 was 49.19.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ondine Biomedical's liquidation value for the six months ended in Jun. 2024 was $-1.44 Mil.

Ondine Biomedical Change In Receivables Historical Data

The historical data trend for Ondine Biomedical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical Change In Receivables Chart

Ondine Biomedical Annual Data
Trend Dec08 Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 -0.40 0.23 0.05 -0.11

Ondine Biomedical Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.01 0.06 -0.17 0.07

Ondine Biomedical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical  (OTCPK:OBIMF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ondine Biomedical's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.169/0.627*91
=49.19

2. In Ben Graham's calculation of liquidation value, Ondine Biomedical's accounts receivable are only considered to be worth 75% of book value:

Ondine Biomedical's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.889-2.923+0.75 * 0.169+0.5 * 0.94
=-1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ondine Biomedical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (OTCPK:OBIMF) » Definitions » Change In Receivables
Comparable Companies
LSE:SBTX LSE:FUM LSE:TRX LSE:SNG LSE:SAR LSE:POLB LSE:AREC LSE:IMM LSE:OPTI LSE:OBD VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
OBI:UK VF5:Germany
Address
1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Website
https://www.ondinebio.com
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.